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Background: Ivacaftor corrects the cystic ﬁbrosis transmembrane conductance regulator (CFTR) gating defect associated with G551D mutation
and is quickly becoming an important treatment in patients with cystic ﬁbrosis (CF) due to this genetic mutation.
Methods: A single-center study was performed in CF patients receiving ivacaftor to evaluate the usefulness of high resolution computed
tomography (HRCT) of the chest as a way to gauge response to ivacaftor therapy.
Results: Ten patients with CF were enrolled for at least one year before and after starting ivacaftor. At time of enrollment, mean age was
20.9 ± 10.8 (range 10–44) years. There were signiﬁcant improvements from baseline to 6 months in mean %FVC (93 ± 16 to 99 ± 16) and
%FEV1 (79 ± 26 to 87 ± 28) but reverted to baseline at one year. Mean sweat chloride levels decreased signiﬁcantly from baseline to one year.
Mean weight and BMI improved at 6 months. Weight continued to improve with stabilization of BMI at one year. Chest HRCT showed signiﬁcant
improvement at one year in mean modiﬁed Brody scores for bronchiectasis, mucous plugging, airway wall thickness, and total Brody scores.
Elevated bronchiectasis and airway wall thickness scores correlated signiﬁcantly with lower %FEV1, while higher airway wall thickness and
mucus plugging scores correlated with more pulmonary exacerbations requiring IV and oral antibiotics respectively.
Conclusions: Based on our ﬁndings, HRCT imaging is a useful tool in monitoring response to ivacaftor therapy that corrects the gating defect
associated with the G551D-CFTR mutation.
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Patients with cystic fibrosis (CF) have progressive lung
disease leading to bronchiectasis and parenchymal structural
changes that is often irreversible with the eventual development
of respiratory failure. Technological innovations and drug
development have significantly impacted the medical care of
the CF population. The majority of these advancements in CF
care involve symptomatic therapy ranging from the treatmentll rights reserved.
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respiratory secretions.
Correcting cystic fibrosis transmembrane conductance
regulator (CFTR) dysfunction may prevent disease progression.
In addition to the limitations that exist for development of
genetic-based therapies, another confounding feature in CF is
the variability of genetic mutations that range from little to no
CFTR protein reaching the cell surface to other mutations
where CFTR protein reaches the epithelial cell surface, but the
defective protein results in markedly less chloride transport
across the apical cell membrane, the so-called gating defect
[1–3]. More recently, there has been some success with the
advent of drugs termed CFTR potentiators that can increase the
ion-channel function by activating cell surface CFTR and thus
restore some transfer of ions and water across the epithelial
surface [1]. Ivacaftor (Vertex Pharmaceuticals Inc., Boston,
MA, USA), an orally bioavailable CFTR potentiator that targets
the G551D mutation, has been shown to increase activity of
defective cell-surface CFTR protein leading to increased
chloride transport at the cell surface in vitro [4–6]. While
treatment with ivacaftor has demonstrated improvements in
lung function, lowering of sweat chloride levels, and increasing
patient weight [4–6], there has been limited work investigating
its effect on lung disease through radiographic imaging.
2. Methods
2.1. Patient population
This single-center, non-blinded, non-randomized pros-
pective cohort study was approved by the Institutional Review
Board at Nationwide Children's Hospital (IRB12-00700).
Patients with CF with at least one G551D-CFTR allele were
started on ivacaftor 150 mg orally every 12 h for one year.
Each patient was instructed to take the drug with a high fat diet
(≥20 gram fat and pancreatic enzymes with snack or meal).
No other alterations of medical care were done with routine
therapy and airway clearance continued according to clinical
status and respiratory cultures.
2.2. Data collection
Demographic data including age, race, gender, weight,
body mass index (BMI), genetic mutations, pancreatic status,
co-morbidities, and tobacco use or secondhand smoke
exposure were collected along with information regarding
hospitalizations and two week courses of antibiotic (oral/
aerosolized and intravenous) one year before and after starting
ivacaftor. Spirometric measurements performed according
to current published standards [7] included forced vital
capacity (FVC), forced expiratory volume in one second
(FEV1), FEV1/FVC ratio, and maximum mid-expiratory
flow rate (FEF25–75%). Pulmonary function was monitored at
multiple time periods, but the data included for analysis was
performed at time of enrollment and 6 months and one year
later. Sweat chloride collections were performed at enrollment
and then repeated 6 months and one year later according toa standardized protocol using the Macroduct collection device
(Wescor, Inc., Logan, UT, USA) [8].2.3. HRCT imaging
High resolution computed tomography (HRCT) scans of
chest were obtained helically at the time of enrollment and then
one year later. The HRCT scans were done using a GE Light
Speed Ultra® or volume CT (General Electric®, Milwaukee,
WI, USA) during voluntary inspiratory breath holding. The
settings for the HRCT were 80–100 kilovolts (peak) (kV[p]),
16–32 mA s, (1 CT scan, 3.8 mSv). To assess the lungs, 4
images (reconstructed in bone algorithm at 0.625 or 1.25 mm
slice thickness) were evaluated at the following specific
anatomic levels: 0.5 cm above the aortic arch, at the carina,
halfway between the carina and 1 cm above the higher
hemi-diaphragm, and 1 cm above the higher hemi-diaphragm.
HRCT images were scored by an experienced pediatric
thoracic radiologist and an experienced pulmonologist using a
modified Brody scoring method [9]. They were not blinded to
study design but scored each HRCT independently of each
other. The scoring system recorded the presence and extent of
specific findings of CF lung disease (bronchiectasis, bronchial
wall thickening, mucus plugging, parenchymal opacities, and
air trapping) in each of the 4 specified levels in the right and
left lungs. Bronchiectasis was defined as the diameter of the
bronchus greater than the accompanying pulmonary artery.
Mucus plugging was defined as the presence of bronchi with
opacification of the lumen, centrilobular nodules, or peripheral
branching structures. Bronchial wall thickening was subjec-
tively assessed based on comparison with other bronchi
throughout the lung. Parenchymal opacities were defined as
foci of non-aerated lung at least the size of a subsegment and
could include atelectasis as well as pneumonia. The extent of an
abnormality was scored as involving ≤ 10% (score = 1), 11–
33% (score = 2), 33–66% (score = 3), N 66% (score = 4) of
the area of lung or number of visible airways. For all findings,
the severity value was multiplied by the extent of the
abnormality to produce a score for that finding. These scores
were added to produce an overall score with a higher score
indicating worsening parenchymal lung disease.2.4. Statistical analysis
In this cohort, demographic and clinical characteristics were
reported as frequency and percentage or mean ± standard
deviation. Depending upon the level of measurement of clinical
parameters, change between baseline and one year was analyzed
by a paired t-test or related samples Wilcoxon signed-rank
test. Similarly, change between baseline, 6 months, and one year
was analyzed by repeated measures analysis of variance
(RM-ANOVA) or related samples Friedman ANOVA by ranks
test. CT scan scores were correlated using Pearson correlations.
Changes in clinical parameters and changes in CT scores were
correlated using spearman correlations. Statistical significance
was set at alpha ≤ 0.05.
Table 2
Alterations in mean weight, BMI, sweat test, and spirometric measurements at
baseline and after 6 and 12 months of ivacaftor therapy.
Baseline 6 months of
therapy
1 year of
therapy
p value
Weight (kg) 46.8 ± 15.2c 51.9 ± 13.5a,b 54 ± 12.7b,c ≤0.001 a
Body mass index 19.5 ± 3a,b 21.1 ± 2.7a 21.5 ± 2.8b 0.002 a
FVC % predicted 92 ± 16a 97 ± 16a 91 ± 21 0.059
FEV1% predicted 78 ± 27
a 86 ± 29a,b 79 ± 30b 0.021 a
FEF25–75%
% predicted
67 ± 44 79 ± 44 69 ± 43 0.167
SD = standard deviation, FVC = mean forced vital capacity, FEV1 = mean
forced expiratory volume in one second, FEF25–75% = mean mid-expiratory
flow rate.
aa bb cc values with same superscripts are significantly different from each other.
a Signiﬁcant at alpha ≤0.05.
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From January 2012 to June 2013, a total of 10 CF patients
with G551D-CFTR mutation were started on ivacaftor therapy
and had HRCT of the chest done at baseline and one year later
and were included in our analysis. At the time of enrollment,
the mean age was 20.9 ± 10.8 (range 10–44) years. At
enrollment, mean sweat chloride for the cohort was 115 ±
5 mmol/L, which decreased significantly after one year of
therapy (50 ± 25 mmol/L, p = 0.023). Other demographics
and clinical characteristics are reported in Table 1. All patients
were Caucasian. Six of 10 were females. Eight of ten were
pancreatic insufficient. None of the patients had cystic fibrosis
related diabetes mellitus (CFRDM) and eight of 10 were also
heterozygous for F508del genotype. There was no specific
pattern to respiratory microbiota (Table 1).
Mean weight and BMI improved from baseline to
6 months, weight continued to improve but there was no
additional improvement in BMI at one year (Table 2). There
were significant improvements from baseline to 6 months in
mean %FVC (93 ± 16 to 99 ± 16) and %FEV1 (79 ± 26 to
87 ± 28) (Table 2). Mean %FVC, %FEV1, and %FEF25–75%,
returned to baseline levels after one year of therapy.
There were no significant differences in the number of
hospitalizations or CF exacerbations that required treatment with
intravenous (IV) or oral/aerosolized antibiotics but there was a
trend towards improvement in all three (Table 3). Five children
(50%) were hospitalized from 1 to 3 times during the year before
therapy, while only 1 (10%) child was hospitalized 1 time after a
year of therapy. Seven (70%) patients experienced 1 to 3 CF
exacerbations that required oral/aerosolized antibiotics before
therapy compared to 5 (50%) after 1 year of therapy. The number
of patients who had CF exacerbations requiring IV antibiotics
decreased from 5 (50%) to 2 (20%).
Structural lung disease was monitored by comparing HRCT
scans of the chest done after one year of therapy with the last
CT scan done (within one year) before starting therapy. HRCT
images were scored separately by an experienced pediatric
thoracic radiologist and an experienced pulmonologist using a
modified Brody scoring method [9]. Inter-rater reliability
between these two readers ranged from r = 0.905 to 0.994Table 1
Demographic and clinical characteristics of the cohort (N = 10).
Characteristics N %
Caucasian 10 100
Male 4 40
Female 6 60
Genotype F508 heterozygous 8 80
Respiratory colonization
Methicillin-resistant Staphylococcus aureus 6 60
Methicillin-sensitive S. aureus 3 30
Pseudomonas aeruginosa 4 40
Gastroesophageal reflux 2 20
Pancreatic insufficiency 8 80
Tobacco use or exposure 0 0%
Cystic fibrosis related diabetes mellitus (CFRDM) 0 0%(p ≤ 0.001) for bronchiectasis, mucous plugging, airway wall
thickness, and total Brody scores. Inter-rater reliability for
parenchymal opacity was r = 0.732 (p = 0.16) at baseline and
r = 0.814 (p = 0.004) after one year of therapy. Changes were
quantified with modified Brody scores [9] (Table 4, Figs. 1 and
2). One patient had a normal HRCT both at baseline and at one
year on therapy. The total mean Brody score significantly
improved along with the scores specific for mucus plugging,
bronchiectasis and airway wall thickness (Table 4, Figs. 1–5).
Mean total modified Brody scores significantly decreased by
13.6 points (bronchiectasis score decreased by 2.7, mucous
plugging decreased by 5.6 points, airway wall thickness
decreased by 5 points). Few patients had parenchymal opacities
or air space disease; thus, scores did not change significantly.
However, one patient had a parenchymal opacity score increase
from 1 to 2, while no patient experienced worsening of lung
disease. Correlations between Brody scores and clinical
parameters are shown in Table 5. Higher bronchiectasis and
airway wall thickness scores correlated significantly with lower
%FEV1. Higher airway wall thickness scores also correlated
with more CF exacerbations requiring IV antibiotics. Higher
mucous plugging scores correlated with more CF exacerbations
requiring oral antibiotics (Table 5). Significant correlations
were noted between changes in total Brody CT scores and
changes in mean %FVC (r = −0.85, p b 0.01), %FEV1
(r = −0.83, p b 0.01) and courses of intravenous antibiotics/
patient (r = 0.66, p = 0.04).Table 3
Mean number of hospitalizations and CF exacerbations that required antibiotics
during one year before and during one year on ivacaftor therapy (N = 10).
One year before
therapy
One year on
therapy
p value
Mean ± SD Mean ± SD Mean ± SD
Hospitalizations 0.6 ± 1.1 0.1 ± 0.5 0.102
Oral/aerosolized antibiotics 1.5 ± 1.3 0.9 ± 1.2 0.193
Intravenous antibiotics 0.8 ± 1.0 0.3 ± 0.7 0.177
SD = standard deviation.
Table 4
Alterations in mean modified Brody scores on high-resolution computed
tomography scans after one year on ivacaftor therapy (N = 10).
Before
therapy
After one
year on therapy
p value
Total Brody score 28.8 ± 16.6 15.2 ± 12.1 0.002 a
Bronchiectasis 11.8 ± 7.6 9.1 ± 6.8 0.001 a
Mucous plug 6.4 ± 4.9 0.8 ± 1.1 0.006 a
Airway wall thickness 9.8 ± 6.7 4.8 ± 5 0.045 a
Parenchymal opacities 0.8 ± 1.4 0.6 ± 1.3 0.169
a Significant at alpha ≤ 0.05.
Fig. 2. Change in mean total modified Brody scores in individual patients after
one year of ivacaftor therapy.
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The most important finding in this study is that CF patients
with G551D-CFTR mutation have improvement on HRCT
imaging with one year of ivacaftor treatment. The majority of
the research involving ivacaftor has used various clinical
parameters including weight, BMI, sweat chloride levels,
nasal potential difference, quality of life scores, and pulmonary
function testing [4–6,10–13], but we strongly felt that
radiographic changes may be a useful tool in gauging response.
In our cohort, ivacaftor therapy was associated with sig-
nificant reduction in mean sweat chloride levels, weight, BMI
and significant improvements in both FVC and FEV1 noted at
6 months but no significant additional improvement in the next
6 months of therapy except in weight. Pulmonary function
measures reverted to baseline at one year. HRCT imaging
demonstrated an improvement in cohort at one year. Higher
HRCT scores correlated with lower %FEV1 and increased use
of antibiotics (intravenous and/or inhaled/oral) for pulmonary
exacerbations of CF.
In comparison to other studies, Ramsey et al. [6] showed
persistent improvement in mean FEV1 throughout 48 weeks
of their study and found significant reduction in pulmonary
exacerbations compared to placebo. However, their cohort was
larger (N = 77), older with a mean age of 25.5 years, and more
importantly, suffered from more advanced lung disease withFig. 1. Change in mean modified Brody scores after one year of ivacaftor
therapy.mean FEV1 of 63.6% predicted. Our cohort was smaller (N =
10), younger (mean age of 21 years) and with a milder disease
(mean FEV1 of 78% predicted), and these differences may
be responsible for lack of significant improvement in %FEV1
after one year of therapy. There was no significant change in
hospitalizations and antibiotic use, but there was a trend
towards improvement for less need of medical intervention.
Improvements in pulmonary function measures were not
sustained at one year which raises the possibility that may be
HRCT is more sensitive to treatment effects than spirometry
especially in patients with mild disease.
Brody scores on HRCT of chest correlated with clinical
parameters. Indicators of advance lung disease such as higher
bronchiectasis and airway wall thickness scores correlated
significantly with lower %FEV1. Higher airway wall thickness
scores also correlated with more CF exacerbations requiring IV
antibiotics and higher mucous plugging scores correlated with
more CF exacerbations requiring oral antibiotics (Table 5).
Sweat chloride did not correlate with Brody scores or clinical
parameters. Correlation between Brody scores and clinical
parameters suggests that change in Brody score was not random
but clearly indicative of improvement.
Our study clearly shows significant improvement in paren-
chymal lung disease with the use of ivacaftor. Improvement in
chloride channel function as determined by the decrease in
sweat chloride may be responsible for improving hydration of
sinus and pulmonary secretions and thinning of mucus. A
change in mucus viscosity may lead to a decrease in bacterial
density, less infection and inflammation and possibly improve-
ment in airway and sino-pulmonary disease. This drug is the
first CFTR modulating medication associated with a reversal of
hallmarks of CF. If used in infants and younger children with
the appropriate genotype, disease progression may be slowed,
but it may also lead to reversal of already developed subtle
progressive lung disease as was seen in this small cohort
using modified Brody scores in the assessment of alterations on
HRCT imaging of the chest.
Fig. 3. Alterations in mucus plugging on high resolution computed tomography imaging of the chest comparing images at baseline and then one year after ivacaftor
therapy.
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design with the lack of placebo group, small sample size and
relatively milder clinical disease. Because of these limitations,
we cannot demonstrate causality regarding the improvement of
parenchymal lung disease on HRCT imaging in these CF
patients and ivacaftor treatment.
Ivacaftor is quickly making an impact in the care of
patients with CF. Due to limited biomarkers available, we
developed this study to assess the utility of HRCT imaging of
the chest. Based on our findings, we showed that HRCT
imaging is a useful tool in monitoring response to this
new therapy that corrects the gating defect associated with
the G551D-CFTR mutation. Further research with larger
cohorts is needed to determine whether parenchymal lung
disease continues to improve beyond the one year period of
treatment.Fig. 4. Alterations in bronchiectasis on high resolution computed tomography imag
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Table 5
Pearson correlations between CT Brody scores and clinical parameters after 1 year on ivacaftor therapy.
%FVC %FEV1 %FEF25_75 Oral antibiotics IV antibiotics Sweat test Weight BMI
Bronchiectasis −0.692 (0.039 a) −0.776 (0.014 a) −0.582 (0.100) 0.381 (0.277) 0.611 (0.061) 0.184 (0.408) 0.251 (0.515) −0.278 (0.468)
Mucous plugging −0.372 (0.325) −0.385 (0.306) −0.439 (0.237) 0.706 (0.023 a) 0.480 (0.160) 0.838 (0.081) −0.151 (0.698) −0.467 (0.205)
Airway wall
thickness
−0.748 (0.021 a) −0.853 (0.003 a) −0.726 (0.027 a) 0.373 (0.289) 0.840 (0.002 a) 0.411
(0.299)
0.254 (0.510) −0.282 (0.463)
Parenchymal
opacity
0.163 (0.765) 0.128 (0.744) 0.127 (0.745) 0.200 (0.956) −0.276 (0.441) 0.304 (0.696) 0.131 (0.736) 0.243 (0.529)
Total Brody score −0.851 (0.004 a) −0.829 (0.006 a) −0.538 (0.135) 0.371 (0.291) 0.661 (0.037 a) 0.442 (0.279) 0.220 (0.570) −0.298 (0.437)
Oral antibiotics: mean number of 2 week courses of oral antibiotics/patient.
I/V antibiotics: mean number of 2 week courses of i/v antibiotics/patient.
IV = intravenous.
Significant correlations (p ≤ 0.05) are in bold.
a Signiﬁcant at alpha ≤0.05.
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